AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Abbvie (ABBV) PT Raised to $212 at Goldman Sachs
February 3, 2025 5:17 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $212.00 (from $208.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance from ABBV shares (+4.7% on Friday vs. XLV -0.3%) was earned in our view, with continued strong momentum from Skyrizi and Rinvoq enabling the delivery of... More
AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance
January 31, 2025 7:37 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.16, $0.10 better than the analyst estimate of $2.06. Revenue for the quarter came in at $15.1 billion versus the consensus estimate of $14.82 billion.
GUIDANCE:
AbbVie sees FY2025 EPS of $12.12-$12.32, versus the consensus of $12.13.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More